5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.24▲ | 6.24▲ | 6.27▲ | 6.28▲ | 4.74▲ |
MA10 | 6.22▲ | 6.29▲ | 6.34▲ | 5.25▲ | 4.21▲ |
MA20 | 6.20▲ | 6.33▲ | 6.41▼ | 4.55▲ | 3.65▲ |
MA50 | 6.27▲ | 6.38▲ | 5.72▲ | 4.02▲ | 3.53▲ |
MA100 | 6.33▲ | 5.58▲ | 4.84▲ | 3.44▲ | N/A |
MA200 | 6.43▼ | 4.74▲ | 4.24▲ | 3.20▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.022▲ | -0.019▼ | -0.081▼ | 0.259▲ | 0.367▲ |
RSI | 68.712▲ | 52.754▲ | 56.498▲ | 77.857▲ | 70.680▲ |
STOCH | 54.167 | 41.486 | 36.599 | 86.911▲ | 71.663 |
WILL %R | 0.000▲ | -21.951▲ | -70.370 | -24.130▲ | -17.941▲ |
CCI | 303.189▲ | 5.119 | -50.020 | 98.769 | 278.883▲ |
CDL | $KYTX Doji Candlestick Pattern Detected | Set Alert |
Wednesday, September 24, 2025 06:05 AM
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 ...
|
Monday, September 15, 2025 10:19 AM
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/09/25 | 6.40 | 6.52 | 6.05 | 6.35 | 284,837 |
24/09/25 | 6.24 | 7.1874 | 6.215 | 6.44 | 957,084 |
23/09/25 | 6.70 | 6.8833 | 6.14 | 6.31 | 716,197 |
22/09/25 | 5.80 | 6.60 | 5.2718 | 6.52 | 1,012,153 |
19/09/25 | 5.16 | 5.99 | 5.13 | 5.80 | 1,525,626 |
18/09/25 | 4.43 | 5.04 | 4.40 | 5.01 | 762,600 |
17/09/25 | 4.00 | 4.4399 | 3.99 | 4.37 | 517,158 |
16/09/25 | 3.89 | 4.10 | 3.87 | 3.87 | 216,643 |
15/09/25 | 4.00 | 4.03 | 3.78 | 3.91 | 346,050 |
12/09/25 | 4.18 | 4.18 | 3.89 | 3.92 | 281,000 |
|
|
||||
|
|
||||
|
|